Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Buy” from Analysts

Neurogene Inc. (NASDAQ:NGNE) has received a consensus rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $84.8333.

A number of brokerages recently weighed in on NGNE. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Neurogene in a research report on Tuesday, June 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Friday, July 17th. UBS Group set a $70.00 price target on Neurogene in a research report on Wednesday, June 3rd. Rodman & Renshaw initiated coverage on Neurogene in a report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price target on the stock. Finally, Guggenheim began coverage on Neurogene in a research note on Tuesday, April 28th. They set a “buy” rating and a $69.00 price objective for the company.

Neurogene Price Performance

Shares of NGNE opened at $35.60 on Friday. The stock has a market capitalization of $562.48 million, a PE ratio of -7.82 and a beta of 1.70. The business’s fifty day moving average price is $33.02 and its 200 day moving average price is $26.20. Neurogene has a 12-month low of $15.93 and a 12-month high of $43.66.

Neurogene (NASDAQ:NGNE) last released its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.09). As a group, research analysts anticipate that Neurogene will post -5.63 earnings per share for the current fiscal year.

Insider Activity at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,200 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $36.13, for a total value of $151,746.00. Following the sale, the chief financial officer owned 84,040 shares of the company’s stock, valued at $3,036,365.20. This trade represents a 4.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 9,600 shares of company stock worth $339,932 in the last three months. 11.68% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. State of Wyoming acquired a new stake in shares of Neurogene in the second quarter valued at approximately $31,000. BNP Paribas Financial Markets increased its position in Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares during the period. Daiwa Securities Group Inc. acquired a new stake in Neurogene in the 4th quarter valued at approximately $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after acquiring an additional 1,059 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Neurogene during the 4th quarter worth $165,000. Institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.